

# Wenbing Duan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336342/publications.pdf>

Version: 2024-02-01

6  
papers

36  
citations

2258059

3  
h-index

2272923

4  
g-index

6  
all docs

6  
docs citations

6  
times ranked

80  
citing authors

#	ARTICLE	IF	CITATIONS
1	The loss or absence of minimal residual disease of $\leq 0.1\%$ at any time after two cycles of consolidation chemotherapy in <i>CBFbMYH11</i> -positive acute myeloid leukaemia indicates poor prognosis. <i>British Journal of Haematology</i> , 2021, 192, 265-271.	2.5	13
2	Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma. <i>Acta Haematologica</i> , 2020, 143, 559-566.	1.4	10
3	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. <i>Annals of Hematology</i> , 2021, 100, 1203-1212.	1.8	10
4	Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities which play significant prognostic roles in Chinese AL amyloidosis patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 208-209.	3.0	3
5	The Lost or Absence of MRD $< 0.1\%$ at Any Time after 2 Cycles of Consolidation Chemotherapy in CFBF-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis. <i>Blood</i> , 2019, 134, 2616-2616.	1.4	0
6	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	1.4	0